热门资讯> 正文

MannKind的Furoscix自动注射装置正在接受FDA审查以扩大标签

2025-12-01 22:21

MannKind Corporation (MNKD) said that the U.S. FDA has accepted its supplemental new drug application for the Furoscix ReadyFlow Autoinjector.
This device is designed to help patients administer their medication more easily.
The FDA has set a target action date of July 26, 2026.
The sNDA is backed by encouraging results from studies that were shared in August 2024.

More on MannKind

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript
MannKind Corporation 2025 Q3 - Results - Earnings Call Presentation
MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
MannKind slides after halting late-stage trial of MNKD-101 for lung disease
MannKind outlines FUROSCIX market expansion and Afrezza pediatric launch strategy following record $82M Q3 revenue

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。